HER2 / ERBB2 nel tumore al seno: studi, trial e ricerca
MBC INTELLIGENCE SEARCH · KNOWLEDGE GRAPH PUBBLICO
HER2 / ERBB2 nel tumore al seno
Pagina documentale costruita esclusivamente da fonti, record e relazioni presenti nel Knowledge Graph MBC. Non formula raccomandazioni terapeutiche.
Copertura documentale
Il Quality Gate pubblico registra 29 supporti documentali, 5 fonti indipendenti e 3 relazioni. Questi valori misurano documentazione e provenienza, non efficacia o appropriatezza clinica.
Documenti indicizzati collegati
- Clinicopathological response and survival outcomes of HER2-low versus HER2-zero early breast Cancer: A systematic review and Meta-analysis — Crossref
- Molecular and immune profiling of HER2-low, HER2 ultra-low, and HER2-null male breast cancer — Crossref
- Revisiting HER2-negative breast cancer in the era of HER2-low and HER2-ultralow expression: Assessment of interobserver variability — Crossref
- Construction of efficacy prediction model for T-DXd treatment of HER2-positive and HER2-low expression breast cancer based on hematological indicators: A real-world study — Crossref
- PRR11 expression in early ER+/HER2-low breast cancer: Association with estrogen receptor positivity and exploratory analysis of prognostic significance. — PubMed / NCBI
- Impact of HER2-low status on survival outcomes in patients with metastatic breast cancer treated with cdk4/6 inhibitors: A single-center experience — Crossref
- Intratumoral heterogeneity derived from synthetic MRI for characterization of HER2 subtypes in breast cancer — Crossref
- Tumor-infiltrating lymphocytes differ across MammaPrint® classifications in breast cancer — Crossref
- Prognostic impact of HER2-low versus HER2-zero expression by hormone receptor status in early breast cancer: a retrospective cohort study — Crossref
- Clinical outcomes and genomic landscape of anti-HER2 antibody-drug conjugates in HER2-positive and HER2-low metastatic breast cancer. — Europe PMC
- Clinical outcomes and genomic landscape of anti-HER2 antibody-drug conjugates in HER2-positive and HER2-low metastatic breast cancer. — PubMed / NCBI
- Neoadjuvant Pyrotinib in HR-positive and HER2-low High-risk Early Breast Cancer — ClinicalTrials.gov
Provenienza dal Knowledge Graph
- — mic_internal_catalog
Collegamenti nel Knowledge Graph
Come interpretare questa pagina
Una relazione documentale non equivale a una raccomandazione. Risultati favorevoli nelle condizioni studiate, non favorevoli nelle condizioni studiate, non concordanti o con dati insufficienti restano consultabili nel motore con la loro provenienza.
Privacy
Questa pagina deriva esclusivamente dal patrimonio scientifico pubblico indicizzato. Il Publisher non usa IP, cookie, account, cronologia, fingerprint o ricerche individuali.
Quality Gate documentale: 86/100 · ultimo aggiornamento Settembre 29, 2026